Ozempic Maker Novo Nordisk Invests Over $1 Billion In New Denmark Production Facility, Closer To Add 3 More From Catalent
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) announced plans to invest approximately $1.20 billion (8.5 billion ...
Novo Nordisk’s Hiring Binge Leaves Danish Firms Starved of Labor
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...
The Herald-Times3h
Novo Holdings says its acquisition of Catalent will be complete 'in the coming days'
Indications are that Novo will be investing in both the plant and the community,” an Indiana University professor said.
Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark
Our daily lives are full of products and processes based on fossil materials, or created using fossil energy sources such as oil and gas. To make significant progress in the green transition, we need ...
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...
Pharmaceutical Technology2d
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Amycretin?
Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity. According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, 4 ...